The company has initiated a Phase II registration trial of a CAR-T that could compete against bluebird and Janssen. CEO Eric Ostertag noted it will dose the first patient in May or June.
Poseida raises $142M in Series C round to advance multiple myeloma CAR-T, preclinical cell therapies
How conversational AI, voice and chatbots will transform patient and consumer engagement [Sponsored]
Kristi Ebong, Orbita SVP Strategy and GM Healthcare Providers, is taking part in a panel discussion at the healthcare investment conference MedCity INVEST in Chicago April 23-24 called, “What Can Alexa/Voice Do for Healthcare?”
CMS launches new value-based payment models for primary care in 2020
Dubbed the CMS Primary Cares Initiative, the program aims to reduce administrative burden for providers, while incentivizing clinicians to spend more time with patients and focus on preventive care.
NeuroSigma wins FDA nod for first non-drug ADHD treatment
The company’s cell phone-sized device delivers low-level electric stimulation to the trigeminal nerve through a patch placed on a patient’s forehead.
Survey: Consolidation, consumerism and telehealth are top healthcare trends in 2019
In a Definitive Healthcare survey of more than 1,000 healthcare leaders, industry consolidation earned 25.2 percent of the votes and the title of the top healthcare trend in 2019.
Evolving healthcare trends call for a different product development approach [Sponsored]
In a Q&A with diagnostics service provider Invetech, President Andreas Knaack talked about some of the evolving healthcare trends that diagnostics companies face, particularly the rise of decentralized healthcare, the aging baby boomer generation …
Opportunities and pitfalls in the healthcare investment landscape: A conversation with McDermott’s Brian Bunn [Sponsored]
Brian Bunn, a partner with international law firm McDermott Will and Emery, shared his perspective on healthcare investment in the runup to the healthcare conference MedCity INVEST in Chicago April 23-24, in which he will take part in a panel discussio…
Arrakis spices up development efforts with $75M Series B round for RNA-targeting drugs
The company has raised more than $100 million since 2017 and plans to use the current funding to build a pipeline of RNA-targeting small molecules.